Bharat Biotech Gets Emergency Use Authorisation for Intranasal Covid-19 Vaccine
06/09/2022 1 minute read
Spread the love
Last month, Bharat Biotech International Limited (BBIL) had said its Covid-19 intranasal vaccine (BBV154) has proven to be safe, well-tolerated, and immunogenic in subjects in controlled clinical trials phase III
